Tocilizumab weekly showed no clear difference in mean change in VAS (higher scores suggest greater disease activity… compared with placebo + 52‐week taper (moderate certainty).
Tocilizumab weekly showed no clear difference in mean change in VAS (higher scores suggest greater disease activity… compared with placebo + 26‐week taper (moderate certainty).
Tocilizumab weekly probably leads to higher mean change in quality of life at ≥ 12 months using the 36‐Item… compared with placebo + 52‐week taper (moderate certainty).
Tocilizumab weekly showed no clear difference in mean change in quality of life at ≥ 12 months using the 36‐Item… compared with placebo + 26‐week taper (moderate certainty).
Tocilizumab weekly probably leads to higher mean change in quality of life at ≥ 12 months using the 36‐Item… compared with placebo + 52‐week taper (moderate certainty).
Tocilizumab weekly showed no clear difference in mean change in quality of life at ≥ 12 months using the 36‐Item… compared with placebo + 26‐week taper (moderate certainty).